Sugi Predict

Sugi Predict / Compounds / SCHEMBL2790329

SCHEMBL2790329

SCHEMBL2790329

Cc1c(S(C)(=O)=O)cc(C(C)(C)C)c(O)c1C(=O)Nc1ccc(S(=O)(=O)C(F)(F)F)cc1C#N

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ AR P10275 5/20 0.33
▸ CXCR2 P25025 2/20 0.33
▸ EPAS1 Q99814 2/20 0.33
▸ GHSR Q92847 2/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ CCR8 P51685 1/20 0.33
▸ ABCB11 O95342 1/20 0.33
▸ ALB P02768 1/20 0.33
▸ PGR P06401 1/20 0.33
▸ ADRA2C P18825 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ ABCC9 O60706 1/20 0.33
▸ ABCC8 Q09428 1/20 0.33
▸ KCNJ11 Q14654 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2788098 0.90 MEN1 (0.36) MEN1KMT2AARCXCR2EPAS1
SCHEMBL2788077 0.89 MEN1 (0.42) MEN1KMT2AARCXCR2EPAS1
SCHEMBL2789217 0.87 MEN1 (0.34) MEN1KMT2AARCXCR2EPAS1
SCHEMBL2790618 0.87 KMT2A (0.34) MEN1KMT2AARCXCR2EPAS1
SCHEMBL2787825 0.87 RXFP1 (0.41) MEN1KMT2AAREPAS1GHSR
SCHEMBL2789521 0.86 PDK1 (0.46) MEN1KMT2A
SCHEMBL13475305 0.85 EPAS1 (0.35) MEN1KMT2AARCXCR2EPAS1
SCHEMBL2786894 0.83 MEN1 (0.42) MEN1KMT2AEPAS1ALDH1A1
SCHEMBL2789079 0.78 MEN1 (0.44) MEN1KMT2A
SCHEMBL2790743 0.78 MEN1 (0.44) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041657-A1 HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDICK A/S (DK) 2010-02-18 — — US claimed
EP-1881961-A1 NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDISK A/S (DK) 2008-01-30 — — EP claimed
WO-2006120178-A1 NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDISK A/S (DK) 2006-11-16 — — WO claimed
US-20100041657-A1 HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDICK A/S (DK) 2010-02-18 — — US disclosed
EP-1881961-A1 NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDISK A/S (DK) 2008-01-30 — — EP disclosed
WO-2006120178-A1 NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDISK A/S (DK) 2006-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041657-A1 HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES RPS12, GPR119, ATP12A MEN1 4083/4885KMT2A 3302/4885AR 4142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.